Download PDF
Onkologische Welt 2012; 03(05): 217
DOI: 10.1055/s-0038-1630242
Gastro-Okologie
Schattauer GmbH

Metastasiertes kolorektales Karzinom: Was leisten neue zielgerichtete Therapieoptionen?

Angelika Bischoff Dr. med.
Further Information

Publication History

Publication Date:
31 January 2018 (online)

Also available at
    Permissions and Reprints

Die EGFR-Blockade ist bisher die einzige etablierte zielgerichtete Therapie beim metastasierten kolorektalen Karzinom. Auf dem 20. Münchener Fachpresse-Workshop “Neues und Wissenswertes aus der Onkologie” beschäftigten sich die Referenten mit dem Stellenwert neuer Substanzen.

 

  • Literatur

  • 1 Douillard JY. et al. Final Results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts;. J Clin Oncol 2011; 29 (Suppl): 3510.
    CrossrefPubMedGoogle Scholar
  • 2 Peeters M. et al. Randomized phase III study of pani- tumumab with fluorouracil, leucovorin, and irini- tecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713.
    CrossrefPubMedGoogle Scholar
  • 3 Arnold D. et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). ASCO Meeting Abstracts 30: CRA3503.